MedTrace Logo

The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus

NCT04275193 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2020-04-28

No results posted yet for this study

Summary

This study evaluates the safety and efficacy of the traditional chinese medicine Zishenqing in the treatment of active systemic lupus erythematosus.

Conditions

Interventions

DRUG

Zishenqing

Zishenqing Granule

DRUG

Placebo

Granule manufactured to mimic Zishenqing(containing 10% composition)

Sponsors & Collaborators

  • RenJi Hospital

    collaborator OTHER

  • Shanghai University of Traditional Chinese Medicine

    lead OTHER

Principal Investigators

  • Liangjing Lv, Ph.D · RenJi Hospital

  • Huanru Qu, Ph.D · Longhua Hospital

  • Zhujing Zhu, Ph.D · Longhua Hospital

  • Ruru Guo, Ph.D · RenJi Hospital

  • Zhongping Xu, Master · Longhua Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2022-03-01
Completion
2022-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04275193 on ClinicalTrials.gov